138 related articles for article (PubMed ID: 9652797)
1. Variable Bcl-2 phenotype in benign and malignant lesions of urothelium.
Bilim VN; Tomita Y; Kawasaki T; Takeda M; Takahashi K
Cancer Lett; 1998 Jun; 128(1):87-92. PubMed ID: 9652797
[TBL] [Abstract][Full Text] [Related]
2. Reciprocal expression of bcl-2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinary bladder.
Li B; Kanamaru H; Noriki S; Yamaguchi T; Fukuda M; Okada K
Urol Res; 1998; 26(4):235-41. PubMed ID: 9759996
[TBL] [Abstract][Full Text] [Related]
3. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
[TBL] [Abstract][Full Text] [Related]
4. The expression of bcl-2 and bcl-6 protein in normal and malignant transitional epithelium.
Lin Z; Kim H; Park H; Kim Y; Cheon J; Kim I
Urol Res; 2003 Aug; 31(4):272-5. PubMed ID: 12879322
[TBL] [Abstract][Full Text] [Related]
5. Expression of bcl-2 in bladder neoplasms is a cell lineage associated and p53-independent event.
Lu QL; Laniado M; Abel PD; Stamp GW; Lalani EN
Mol Pathol; 1997 Feb; 50(1):28-33. PubMed ID: 9208811
[TBL] [Abstract][Full Text] [Related]
6. Expression of bcl-2 and p53 oncoproteins in schistosomiasis-associated transitional and squamous cell carcinoma of urinary bladder.
Chaudhary KS; Lu QL; Abel PD; Khandan-Nia N; Shoma AM; el Baz M; Stamp GW; Lalani EN
Br J Urol; 1997 Jan; 79(1):78-84. PubMed ID: 9043502
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder.
Shiina H; Igawa M; Urakami S; Honda S; Shirakawa H; Ishibe T
J Clin Pathol; 1996 May; 49(5):395-9. PubMed ID: 8707954
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53.
Ong F; Moonen LM; Gallee MP; ten Bosch C; Zerp SF; Hart AA; Bartelink H; Verheij M
Radiother Oncol; 2001 Nov; 61(2):169-75. PubMed ID: 11690683
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder.
Uchida T; Minei S; Gao JP; Wang C; Satoh T; Baba S
Oncol Rep; 2002; 9(2):253-9. PubMed ID: 11836589
[TBL] [Abstract][Full Text] [Related]
10. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
[TBL] [Abstract][Full Text] [Related]
11. Expression of bcl-2 and bcl-X in bladder cancer.
Kirsh EJ; Baunoch DA; Stadler WM
J Urol; 1998 Apr; 159(4):1348-53. PubMed ID: 9507882
[TBL] [Abstract][Full Text] [Related]
12. [Expression of the bcl-2 and bax oncoprotein in TCC and its clinical significances].
Yang B; Gu F; Wang X
Zhonghua Wai Ke Za Zhi; 1997 Oct; 35(10):602-4. PubMed ID: 10678049
[TBL] [Abstract][Full Text] [Related]
13. Expression of transforming growth factor beta1 and its receptors in normal human urothelium and human transitional cell carcinomas.
Izadifar V; de Boer WI; Muscatelli-Groux B; Maillé P; van der Kwast TH; Chopin DK
Hum Pathol; 1999 Apr; 30(4):372-7. PubMed ID: 10208456
[TBL] [Abstract][Full Text] [Related]
14. p53 and bcl-2 overexpression as associated risk factors in patients 40 years old or less with transitional cell carcinoma of the bladder.
Asci R; Yildiz L; Sarikaya S; Buyukalpelli R; Yilmaz AF; Kandemir B
Urol Int; 2001; 67(1):34-40. PubMed ID: 11464113
[TBL] [Abstract][Full Text] [Related]
15. Cytokeratins in normal and malignant transitional epithelium. Maintenance of expression of urothelial differentiation features in transitional cell carcinomas and bladder carcinoma cell culture lines.
Moll R; Achtstätter T; Becht E; Balcarova-Ständer J; Ittensohn M; Franke WW
Am J Pathol; 1988 Jul; 132(1):123-44. PubMed ID: 2456018
[TBL] [Abstract][Full Text] [Related]
16. P53 overexpression in bladder urothelial neoplasms: new aspect of World Health Organization/International Society of Urological Pathology classification.
Kalantari MR; Ahmadnia H
Urol J; 2007; 4(4):230-3. PubMed ID: 18270948
[TBL] [Abstract][Full Text] [Related]
17. Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract.
Nakanishi K; Tominaga S; Hiroi S; Kawai T; Aida S; Kasamatsu H; Aurues T; Hayashi T; Ikeda T
Virchows Arch; 2002 Dec; 441(6):559-63. PubMed ID: 12461612
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma.
Messing EM
Cancer Res; 1990 Apr; 50(8):2530-7. PubMed ID: 1690599
[TBL] [Abstract][Full Text] [Related]
19. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
20. Detection of p53 and bcl-2 protein in carcinoma of the renal pelvis and ureter including dysplasia.
Furihata M; Sonobe H; Ohtsuki Y; Yamashita M; Morioka M; Yamamoto A; Terao N; Kuwahara M; Fujisaki N
J Pathol; 1996 Feb; 178(2):133-9. PubMed ID: 8683378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
